David B Wells

Director David B Wells purchases 48,400 HIMS shares at $24.24 for $1,172,974.00; holdings rise 27.5% to 224,417 shares

David B Wells, a Director of Hims & Hers Health, purchased 48,400 shares at $24.24 on 2026-05-26 in an open-market transaction totaling $1,172,974.00, increasing his holdings by 27.5% to 224,417 shares. The purchase occurs against mixed fundamentals: Hims reported $608,104,000.00 in latest-quarter revenue with strong 59.0% annual growth, yet recorded a net loss of $-92,115,000.00. His prior trading at HIMS shows 2 completed sells (on 2024-11-13 and 2024-02-28) that both posted substantially positive 90-day returns (+45.3% and +45.2% respectively), indicating poorly-timed exits that missed significant post-sale gains. The buy transaction itself is material in size relative to his historical trading activity and represents a discrete accumulation gesture in a growth-stage healthcare company operating at net loss.

Director David B Wells sold 28,638 shares of TTD at $79.88; stock now $77.50, -44.4% from 52-week high

Director David B Wells sold 28,638 shares (28.6K) at $79.88 on 2025-05-13, reducing his holdings by approximately 30% to 66,985 shares post-transaction. The sale occurred at a price substantially above the current $77.50 level, though the stock remains deeply depressed relative to its 52-week high of $139.51. Wells' prior trades at TTD have shown mixed timing: his 2023-07-13 sale generated a -5.8% 90-day return (well-timed), while his 2023-07-11 sale generated a +5.0% 90-day return (poorly timed). His cross-ticker track record shows a 25.00% well-timed rate across 4 prior sells, with an average 90-day return of +22.4%, indicating his sales have historically missed subsequent gains more often than not. The current sale's significance is moderate given the substantial prior holdings reduction and the company's strong fundamentals (25.6% annual revenue growth, $616.0M quarterly revenue), though the depressed valuation relative to the 52-week range and the conflicting signals from his recent transaction history merit attention.

Director WELLS DAVID B sold 40,000 HIMS shares at $29.99 on 2024-11-13; stock now $20.85 (-25.2% from 52-week high).

Director WELLS DAVID B sold 40,000 shares (40.0K shares) at $29.99 on 2024-11-13, reducing holdings by 20.4% to 156,036 shares remaining. The transaction's timing requires context: the stock has since declined to $20.85, placing it -25.2% from its 52-week high and -8.6% over the past 30 days. Across his cross-ticker track record, the insider's prior 3 sells showed a 90-day well-timed rate of 33.33%, suggesting mixed execution. At HIMS specifically, his one prior sale on 2024-02-28 proved poorly timed—the stock returned +45.2% over the subsequent 90 days. The company's fundamentals remain mixed: revenue of $401,556,000.00 with +65.5% annual growth, and the latest quarter showed positive net income of $75,588,000.00, yet the full-year result was unprofitable. The sale's significance lies in the material position reduction against a backdrop of strong revenue growth but historical unprofitability, warranting monitoring of whether this reflects reassessment of company trajectory or routine portfolio management.